Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
Pipeline News and Updates
Picture

Update for August 17, 2021

8/16/2021

 
Regulatory Update
 
The FDA approved belzutifan (Welireg, Merck), on 8/13/2021, to treat von Hippel-Lindau (VHL) disease for patients who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery.
 
The FDA agreed with the Advisory Committee recommendation and rejected AstraZeneca’s and FibroGen’s roxadustat for the treatment of anemia in patients with chronic kidney disease and requested a new efficacy trial.
 
The FDA rejected Sesen Bio’s oportuzumab monatox, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer, and requested additional clinical and manufacturing data. 
 
In August 2021, the FDA delayed the PDUFA for Merck’s gefapixant, from December 2021 to March 2022, to allow more time for a full review of the drug. 
 
Ipsen withdrew the NDA for palovarotene to allow time for additional analyses and evaluation of data.
 
The FDA has placed a hold for a clinical trial evaluating Aprea Therapeutics’ eprenetapopt with acalabrutinib or with venetoclax and rituximab for the treatment of lymphoid malignancies. Three trials evaluating eprenetapopt in combination with azacitidine for the treatment of myelodysplastic syndrome has also been put on hold.
 
Announced Research Updates
 
The Department of Veterans Affairs will not include aducanumab on its national formulary due to safety and efficacy concerns. Use of the drug is restricted to specific patients when prescribed by dementia experts. Biogen is restricted from promoting the drug to VA prescribers.
 
Lilly announced 16-week results from the 52-week, Phase III, ADvocate 1 and ADvocate 2 trials, where more patients treated with lebrikizumab achieved an Investigator Global Assessment (IGA) score of clear or almost clear skin with a 2-point or greater improvement in the IGA score and a 75% or greater improvement in their EASI score compared to placebo in patients with moderate-to-severe atopic dermatitis.
 
Travere announced interim results after 36-weeks from the first 280 patients enrolled in the Phase III, PROTECT trial, where treatment with sparsentan reduced the urine protein-to-creatinine ratio by 49.8% compared to a 15.1% decrease with irbesartan in IgA nephropathy (IgAN) patients with persistent proteinuria despite active ACE or ARB treatment. Travere plans to file an NDA and MAA in the first half of 2022.
 
Published Research Updates
 
In the 52-week, 1,444 patient, Phase III SURPASS-3 trial, treatment with tirzepatide reduced HbA1c by 1.93% with 5 mg, 2.2% with 10 mg and 2.37% with 15 mg compared to 1.34% with insulin degludec in insulin-naive patients with type 2 diabetes and inadequate glycemic control on stable doses of metformin with or without an SGLT-2 inhibitor.The reduction in HbA1c met the criteria for non-inferiority. Tirzepatide also decreased bodyweight from 7.5 kg to 12.9 kg compared to gain of 2.3 Kg with insulin degludec. 
 
In the three-month, 2,199 patient, Phase III, CONCERTO trial, treatment with laquinimod did not improve the time to confirmed disease progression compared to placebo in patients with relapsing-remitting multiple sclerosis.
 
In an 8-week, 25 patient, open-label, phase II trial, treatment with remetinostat 1% gel resulted in at least a 30% decrease in tumor diameter in 70% of tumors and complete resolution in 54.8% of tumors in patients with basal cell carcinoma.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    March 2023
    February 2023
    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.